Ask AI
See Activity Collection
ProCE Banner Activity

Precision in Practice: Implementing HER2 Testing and HER2-Directed Therapy in Gynecologic Cancers

Slideset

These downloadable slides examine the evolving role of HER2 as a clinically actionable biomarker in gynecologic cancers, with emphasis on how HER2 testing, interpretation of test results, and treatment evidence should inform patient selection and management. Differences among HER2 protein expression, gene amplification, and activating mutations; practical issues in IHC and ISH testing; causes of discordant or heterogeneous results; and guideline-aligned testing approaches across endometrial, cervical, ovarian, and other gynecologic malignancies are also reviewed. The slides summarize clinical evidence for HER2-directed therapy, including trastuzumab-based strategies and antibody–drug conjugates such as trastuzumab deruxtecan, with data from studies including DESTINY-PanTumor02 and STATICE demonstrating activity in HER2-expressing endometrial, cervical, ovarian, and uterine carcinosarcoma populations.

Released: August 20, 2026

Begin Activity

Share

Faculty

Dana M. Chase

Dana M. Chase, MD

Scientific and Medical Consultant
Clinical Professor of Medicine
Division of Gynecologic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California
Kathleen N. Moore

Kathleen N. Moore, MD, MS, FASCO

Deputy Director & Director of Phase 1 Research
Fred & Pamela Buffett Cancer Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

Oncologists, gynecologic oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other community HCPs caring for patients with endometrial, ovarian, and cervical cancers. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement guideline-aligned HER2 testing, interpretation, and reporting workflows in gynecologic cancers, including appropriate handling of equivocal or low-expression results

  • Appraise established and emerging HER2-directed evidence across endometrial, cervical, and ovarian cancers and apply evidence-based approaches to patient selection and sequencing

  • Develop proactive, team-based strategies to monitor, recognize, and manage treatment-related toxicities associated with HER2-directed therapies to support treatment continuity and patient safety

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and generating clinical case(s) or scenario(s). All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.